Earnings per Share (EPS) loss is anticipated to be $0.27 with projected revenue of around $29.7 million.
The Price-to-Earnings (P/E) ratio stands at 35.87, indicating the premium investors are willing to pay for LFCR’s earnings.
LFCR’s current ratio is 1.83, showcasing a solid liquidity position to cover short-term liabilities.

Lifecore Biomedical, Inc. (NASDAQ: LFCR) is preparing to release its quarterly earnings on January 2, 2025. As a fully integrated contract development and manufacturing organization, LFCR plays a significant role in the biomedical sector. Wall Street anticipates an earnings per share (EPS) loss of $0.27, with projected revenue of around $29.7 million.

LFCR’s financial metrics provide a deeper understanding of its market position. The company has a price-to-earnings (P/E) ratio of 35.87, indicating the premium investors are willing to pay for its earnings. This is complemented by a price-to-sales ratio of 2.18, showing that investors pay $2.18 for every dollar of sales.

The enterprise value to sales ratio of 3.20 highlights LFCR’s total valuation in relation to its sales. Additionally, the enterprise value to operating cash flow ratio stands at 55.06, offering insight into how the company’s valuation compares to its cash flow from operations. This can be crucial for understanding the company’s financial health.

LFCR’s earnings yield is approximately 2.79%, providing a perspective on the potential return on investment. The company’s debt-to-equity ratio is notably negative at -32.48, indicating a stronger equity position compared to its debt. This can be seen as a positive sign of financial stability.

Lastly, LFCR’s current ratio of 1.83 suggests that the company has a solid liquidity position, capable of covering its short-term liabilities. This is an important metric for investors, as it reflects the company’s ability to meet its financial obligations in the near term.